Therefore, a therapeutic strategy that targets tumor-specific DNA repair pathways through RAD52 inactivation may be a promising approach to improve therapy efficacy since it can result in an increased tumor cells sensitization to cell death and a decreased toxicity to normal cells. The gene discussed is RAD52; the disease is neoplasm.